Premenopausal serum sex hormone levels in relation to breast cancer risk, overall and by hormone receptor status-Results from the EPIC cohort

Kaaks, Rudolf; Tikk, Kaja; Sookthai, Disorn; Schöck, Helena; Johnson, Theron; Tjønneland, Anne; Olsen, Anja; Overvad, Kim; Clavel‐Chapelon, Françoise; Dossus, Laure; Baglietto, Laura; Rinaldi, Sabina; Chajès, Véronique; Romieu, Isabelle; Boeing, Heiner; Schütze, Madlen; Trichopoulou, Antonia; Λάγιου, Παγώνα; Trichopoulos, Dimitrios; Palli, Domenico; Sieri, Sabina; Tumino, Rosario; Ricceri, Fulvio; Mattiello, Amalia; Buckland, Genevieve; Quiŕos, J. Ramón; Sánchez, María José; Amiano, Pilar; Chirlaque, María Dolores; Barricarte, Aurelio; Bueno-De-Mesquita, H. Bas; Gils, Carla H. van; Peeters, Petra H.M.; Andersson, Anne; Sund, Malin; Weiderpass, Elisabete; Khaw, Kay Tee; Wareham, Nick; Key, Timothy J.; Travis, Ruth C.; Merritt, Melissa A.; Gunter, Marc J.; Riboli, Elio; Lukanova, Annekatrin

doi:10.1002/ijc.28528

Cited by 79 publications

(81 citation statements)

References 43 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…17,18 Briefly, two different dating methods were used: "forward" dating counted forward from the woman's reported date of the start of her last menses, whereas "backward" dating counted backward from the date of the start of her next menses after blood donation. When both dating methods were available, the backward dating method was used to determine the menstrual cycle phase as it is known to be more accurate than forward dating.…”

Section: Blood Sample Collection and Storagementioning

confidence: 99%

Endogenous androgens and risk of epithelial invasive ovarian cancer by tumor characteristics in the European Prospective Investigation into Cancer and Nutrition

et al. 2014

Self Cite

View full text Add to dashboard Cite

The role of endogenous androgens and sex hormone‐binding globulin (SHBG) in ovarian carcinogenesis is poorly understood. Epithelial invasive ovarian cancer (EOC) is a heterogeneous disease and there are no prospective data on endogenous androgens and EOC risk by tumor characteristics (histology, grade, stage) or the dualistic model of ovarian carcinogenesis (i.e. type I vs. type II, leading to less or more aggressive tumors). We conducted a nested case–control study in the European Prospective Investigation into Cancer and Nutrition (EPIC) cohort evaluating androgens and SHBG and invasive EOC risk by tumor characteristics. Female participants who provided a blood sample and were not using exogenous hormones at blood donation were eligible (n = 183,257). A total of 565 eligible women developed EOC; two controls (n = 1,097) were matched per case. We used multivariable conditional logistic regression models. We observed no association between androgens, SHBG and EOC overall. A doubling of androstenedione reduced risk of serous carcinomas by 21% (odds ratio (OR)log2 = 0.79, 95% confidence interval [CI] = [0.64–0.97]). Moreover, associations differed for low‐grade and high‐grade carcinomas, with positive associations for low‐grade and inverse associations for high‐grade carcinomas (e.g. androstenedione: low grade: ORlog2 = 1.99 [0.98–4.06]; high grade: ORlog2 = 0.75 [0.61–0.93], phet ≤ 0.01), similar associations were observed for type I/II tumors. This is the first prospective study to evaluate androgens, SHBG and EOC risk by tumor characteristics and type I/II status. Our findings support a possible role of androgens in ovarian carcinogenesis. Additional studies exploring this association are needed.

show abstract

Section: Blood Sample Collection and Storagementioning

confidence: 99%

Endogenous androgens and risk of epithelial invasive ovarian cancer by tumor characteristics in the European Prospective Investigation into Cancer and Nutrition

et al. 2014

Self Cite

View full text Add to dashboard Cite

show abstract

“…Beside evidence for an increased risk of breast cancer in relation to an elevated free concentrations of, there is also a possible increase in risk with higher estradiol levels for breast cancer before age 50 years, namely before the menopausal transition [90][91][92]. This interrelation between the level of free estradiol and breast cancer risk in premenopausal women and the presented interrelation among the age at menopause, menopausal status, and body fatness may be considered as evidence for the clinical importance of this study in addition to the new epidemiological data on body composition changes during the menopausal transition from the aspect of menopausal status.…”

Section: Discussionmentioning

confidence: 99%

Body fatness and endogenous sex hormones in the menopausal transition

et al. 2016

View full text Add to dashboard Cite

a b s t r a c tBackground: Age at the final menstrual period is of clinical and public health interest because the age at which natural menopause occurs may be a marker of ageing and health, and in general the menopausal transition increases the risk of many diseases, e.g. redistribution in the pattern of adiposity during the menopausal transition may increase risk of metabolic disease. The purpose of this research was to study the relationship between the menopausal status and body fatness. Subjects and methods: A random sample of 1932Hungarian women was studied. Body composition was estimated by body impedance analysis. In a subsample free estradiol and progesterone levels in saliva were quantified. Results: Body fat mass increased until the late 50s and then had a decrease through senescence. Premenopausal women who were much older than the median age at menopause had a higher amount of fat than their postmenopausal age-peers, while postmenopausal women, whose menopause occurred much earlier than the median age at menopause, had less fat than their premenopausal age-peers. The body fat mass in premenopausal women with low levels of sex hormones was always below the agemedian value of the menopausal status subgroups, while the body fat mass of postmenopausal women with high levels of sex hormone levels was above the age-median values. Conclusions: The analysis of body fatness in the menopausal transition revealed that (1) the rate of reproductive ageing and the body fat pattern were significantly related, and (2) body fat mass of women with unexpected levels of sex hormones was related more to their hormonal levels than to their menopausal status or their age. Thus future epidemiological screenings of women exposed to higher levels of menopause-related health risks should be expanded beyond the estimation of menopausal status based only on menstrual history to include sex hormone level assessment, as well as body composition analysis.

show abstract

“…Given the association between hormone levels in breast carcinoma patients and their prognosis (Farhat et al, 2013;Kaaks et al, 2014), it would be useful to assess whether the mEH Tyr113His and His139Arg mutations interact with hormone levels to influence patients' prognosis. We were unable to address this question because most of the studies in our metaanalysis did not report detailed data regarding hormone levels.…”

Section: Discussionmentioning

confidence: 99%

Meta-analysis of microsomal epoxide hydrolase gene polymorphism and the risk of breast carcinoma

Zhong

et al. 2015

Genet. Mol. Res.

View full text Add to dashboard Cite

ABSTRACT. Carcinogenesis of breast carcinoma is very complicated. Previous studies have suggested conflicting results regarding the association between Tyr113His and His139Arg microsomal epoxide hydrolase (mEH) gene polymorphisms and risk of breast carcinoma. We conducted a meta-analysis to examine the relationship between these polymorphisms and breast carcinoma risk. We searched the PubMed, EMBASE, and Google Scholar databases to identify relevant studies. After extracting relevant data, the association between mEH polymorphisms and susceptibility to breast carcinoma was examined by meta-analysis. Odds ratios (ORs) with 95% confidence intervals (CIs) were calculated to assess the strength of the association. Seven studies were identified that included 6357 cases and 8090 controls. The mEH His-allele was not associated with the risk of breast carcinoma based on the allelic contrast model (OR = 0.99, 95%CI = 0.94-1.04, P = 0.58), dominant genetic model (OR = 1.14, 95%CI = 0.88-1.48, P = 0.33), or recessive genetic model (OR = 1.03, 95%CI = 0.96-1.10, P = 0.43). Similarly, the mEH Arg-allele was not associated with breast carcinoma risk based on the allelic contrast model (OR = 0.97, 95%CI = 0.91-1.04, P = 0.44), dominant genetic model (OR = 1.01, 95%CI = 0.84-1.21, P = 0.94), or recessive genetic model (OR = 1.04, 95%CI = 0.96-1.12, P = 0.35). Subgroup analysis based on ethnicity showed no association between the polymorphisms and risk of breast carcinoma. Thus, the Tyr113His and His139Arg mEH polymorphisms may not be risk factors for breast carcinoma.

show abstract

Premenopausal serum sex hormone levels in relation to breast cancer risk, overall and by hormone receptor status-Results from the EPIC cohort

Cited by 79 publications

References 43 publications

Endogenous androgens and risk of epithelial invasive ovarian cancer by tumor characteristics in the European Prospective Investigation into Cancer and Nutrition

Endogenous androgens and risk of epithelial invasive ovarian cancer by tumor characteristics in the European Prospective Investigation into Cancer and Nutrition

Body fatness and endogenous sex hormones in the menopausal transition

Meta-analysis of microsomal epoxide hydrolase gene polymorphism and the risk of breast carcinoma

Contact Info

Product

Resources

About